摘要
目的探讨左西孟旦治疗急性心肌梗死后左心衰竭患者LVEF、LVEDD以及NT-proBNP、hs-CRP指标的变化及其临床意义。方法随机选择62例诊断明确的急性心肌梗死早期合并左心力衰竭并需要正性肌力药物治疗的患者,随机分为左西孟旦治疗组和对照组。左西孟旦治疗组给予静脉注射左西孟旦药物治疗;对照组应用多巴酚丁胺药物治疗。监测两组患者治疗前后左室射血分数LVEF、LVEDD以及NT-proBNP、hs-CRP等指标的变化,并分析其临床意义。结果左西孟旦治疗组在提高LVEF及降低LVEDD方面优于对照组(P<0.05);治疗24h及1周后,与对照组比较,左西孟旦治疗组患者的hs-CRP、NT-proBNP等项指标均明显降低(P<0.05)。结论左西孟旦可以明显提高患者LVEF,降低LVEDD,有效降低NT-proBNP及hs-CRP。
Objective To discuss the change arid clinical significance of LVEF,LVEDD,NT-proBNP,hs-CRP of levosimendan in the treatment of left ventricular failure after acute myocardial infarction. Methods Sixty-two patients with left ventricular failure after acute myocardial infarction and need for inotropic agents were included. They were randomly divided into levosi- mendan treatment group and control group. Levosimendan treatment group was given intravenous injection of levosimendan. The control group was treated with dobutamine. The change of LVEF, LVEDD, NT-proBNP, hs-CRP were observed before and after treatment,and the clinical significance was analyzed. Results The levosimendan treatment group was superior to the control group in improving LVEF and reducing LVEDD. After treatment of 24 h and 1 week, the levels of hs-CRP and NT-proBNP in the patients treated with levosimendan were significantly lower than those in the control group (P〈0. 05). Conclusion This study indicates LVEF was increased significantly in levosimendan group, and LVEDD, NT-proBNP and high-sensitivity CRP were decreased.
出处
《滨州医学院学报》
2017年第3期175-177,214,共4页
Journal of Binzhou Medical University
关键词
左西孟旦
急性心肌梗死
左心衰竭
Ca2+增敏剂
正性肌力药
levosimendan,acute myocardial infarction,left ventricular failure,calcium sensitizers, positive inotropic agents